Atomo Diagnostics
- Short interest
- 0.26%
- +0.24 pp 30d
- as of 7 Aug 2023
- Reported shorts
- 1.6M
- Shares on issue
- 605.869M
Atomo Diagnostics (AT1) Short Interest
Atomo Diagnostics (ASX:AT1) had 0.26% of shares reported as short positions as of 7 Aug 2023, representing 1,552,633 shares. Atomo Diagnostics operates in the Health Care Equipment & Services industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Atomo Diagnostics
Atomo Diagnostics specializes in the design and production of rapid diagnostic test devices, focusing on user-centered design to improve usability and accuracy. The company is recognized for its innovative platforms that simplify testing processes and reduce user errors, positioning it as a leader in the global rapid diagnostics market.
Company profile →Atomo Diagnostics (ASX:AT1) has 0.26% of its shares on issue reported as short positions as of 7 Aug 2023, or about 1,552,633 shares. Over the past 30 days that figure has risen 0.24 percentage points, and over 90 days it has risen 0.24 percentage points. Its highest recorded short interest was 0.79% in October 2020. AT1 is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads AT1 today
- Zanger BreakoutWatchScore 42rank 182 of 1942
- CAN SLIMWatchScore 9rank 1216 of 1541
- Minervini Trend TemplateNot a candidate
- Crowded-Short BreakoutWatchScore 9rank 1080 of 1500
- Quality compoundersWatchScore 25rank 516 of 1669
Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
AT1 fundamentals
In the year to 30 Jun 2026, Atomo Diagnostics (ASX:AT1) recorded revenue of A$5.2M and a net loss after tax of A$3.5M. A year earlier it recorded revenue of A$3.2M and a net loss after tax of A$5.0M. Year-on-year growth: revenue +60.9% (FY). Net margin −67.2%, return on equity −47.9% (FY). Figures are in AUD, the company's reporting currency; source: Yahoo Finance, as at 2 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest AT1 news
All news- Biocurious: Atomo is girding for the STD ‘comeback tour’ no-one wants to see
stockhead · 6 Oct 2026
- 2026 Notice of Annual General Meeting
asx · 1 Oct 2026
- FY26 Results and Strategy Presentation
asx · 23 Sept 2026
Company details
website
address
More Health Care Equipment & Services Stocks
Other shorted stocks in this sector
Be the first to discuss AT1
Start a research thread or post the first pulse update